91 results
8-K
EX-99.2
PHASQ
PhaseBio Pharmaceuticals Inc
16 May 24
Other Events
4:28pm
Portion of Deferred Sublicense Revenue
Accrued Clinical and MFG, and Other
Accrued Interest
Short Term Operating Lease Liability
Long Term Portion of JMB … Debt
Long Term Operating Lease Liability
Long Term Portion of Deferred Sublicense Revenue
Development Derivative
Total Liabilities
Common Stock
APIC
8-K
EX-99.1
PHASQ
PhaseBio Pharmaceuticals Inc
16 May 24
Other Events
4:28pm
Long Term Portion of JMB Debt
Long Term Operating Lease Liability
Long Term Portion of Deferred Sublicense Revenue
Development Derivative
Total
8-K
EX-99.2
PHASQ
PhaseBio Pharmaceuticals Inc
12 Mar 24
Entry into a Material Definitive Agreement
4:34pm
Liability
Long Term Portion of JMB Debt
Long Term Operating Lease Liability
Long Term Portion of Deferred Sublicense Revenue
Development Derivative
Total
8-K
EX-99.1
PHASQ
PhaseBio Pharmaceuticals Inc
12 Mar 24
Entry into a Material Definitive Agreement
4:34pm
of Deferred Sublicense Revenue
Accrued Clinical and MFG, and Other
Accrued Interest
Short Term Operating Lease Liability
Long Term Portion of JMB … Debt
Long Term Operating Lease Liability
Long Term Portion of Deferred Sublicense Revenue
Development Derivative
Total Liabilities
Common Stock
APIC
8-K
EX-99.3
PHASQ
PhaseBio Pharmaceuticals Inc
12 Mar 24
Entry into a Material Definitive Agreement
4:34pm
Interest
Short Term Operating Lease Liability
Long Term Portion of JMB Debt
Long Term Operating Lease Liability
Long Term Portion of Deferred Sublicense
8-K
EX-99.1
yr9kgqrib0bpdovb
29 Nov 23
Other Events
4:55pm
8-K
EX-99.2
gwi0f1m0cyz505o ejc
29 Nov 23
Other Events
4:55pm
8-K
EX-99.1
cffqu ds3hww5t9393
27 Sep 23
Other Events
8:52am
8-K
EX-99.2
gyazrrqz0yyqz0n
25 Aug 23
Other Events
12:34pm
8-K
EX-99.1
sr1jh4q3bx l7iih
25 Aug 23
Other Events
12:34pm
8-K
EX-99.1
8cuarz7 49
30 Jun 23
Other Events
4:21pm
8-K
EX-99.1
sza9gb56qt67
30 May 23
Other Events
4:02pm
8-K
EX-99.1
gnxqgpt
10 May 23
Other Events
8:08am
8-K
EX-99.1
v9biorugkfi
23 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:33am
8-K
EX-99.1
e2jmqepzydnrmq8g c3u
23 Nov 22
Departure of Directors or Certain Officers
4:08pm
8-K
EX-99.1
dqlwhndqioe
12 Aug 22
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:32am
8-K
EX-99.2
qpok1hf cd
12 Aug 22
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8:32am
8-K
EX-99.1
nfnf4b
16 May 22
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
12:00am